Objective: We investigated the intraocular pressure (IOP) -lowering effect and safety of 0.002% omidenepag isopropyl (OMDI) ophthalmic solution by retrospectively evaluating the short-term results for 6 months.
Subjects and methods: The study included 83 eyes of 83 glaucoma patients who were prescribed OMDI. The patients were divided into two groups-the newly prescribed group, which consisted of 45 eyes of 45 patients who started using OMDI alone without continuing the use of any previously prescribed drugs, and the switched group, which consisted of 38 eyes of 38 patients who switched from prostaglandin (PG) -related drugs to OMDI. Changes in IOP and the frequency of adverse reactions were evaluated for 6 months after the start to OMDI.
Results: In the newly prescribed group, the mean IOP (mmHg) significantly decreased at all time points of observation after the start of instillation (15.2±3.7 after 1 month, 15.1±4.9 after 3 months, and 14.9±2.9 after 6 months) compared to the value of 18.0±4.5 before starting OMDI use. Meanwhile, in the switched group, the mean IOP (mmHg) was 15.6±3.8 before switching, 15.8±4.3 after 1 month, 15.2±3.0 after 3 months, and 15.1±3.5 after 6 months; no statistically significant differences were found between mean IOP values before switching and those after switching. Adverse reactions were noted in eight patients (17.8%) in the newly prescribed group. Although cystoid macular edema occurred in one patient (2.2%) 3 months after the start of instillation, the symptom improved after the discontinuation of instillation. No patient exhibited symptoms, such as eyelash growth, deepening of the upper eyelid sulcus, and periocular pigmentation, characteristic of PG-related drugs.
Conclusion: Although this study showed that OMDI might have an IOP-lowering effect comparable to PG-related drugs, extra attention to the occurrence of cystoid macular edema must be paid even in phakic eyes.
Nippon Ganka Gakkai Zasshi (J Jpn Ophthalmol Soc) 126: 19-26, 2022.